development of novel solutions to clinical problems
The applications of surgical sealants, glues and wound closure are many and are rapidly multiplying as more credible data is generated on each application and as physicians gain comfort in working with the products in routine clinical practice.
Below is a sample of surgical sealants, glues and wound closure applications by clinical area:
Source: MedMarket Diligence, LLC; [...]
The biggest hurdle remaining to the creation of viable, commercialized embryonic or adult stem cells is to develop the ability to differentiate cells into various types of cells and to determine how these differentiated cells behave when cultivated in large numbers in the laboratory. In many cases, researchers are still uncertain whether the cells retain [...]
(Below is an excerpt from "Surgical Sealants, Glues and Wound Closure Worldwide Market, 2009-2013.")
Natural hemostats such as gelatin, collagen and thrombin were first developed as hemostatic agents, followed by mixes and fibrin sealants. More recently, companies have introduced synthetic sealants and hemostats that accelerate the process of blood clotting and provide a stronger seal that [...]
In the medical technology arena, the markets that draw the most attention (i.e., investment) are those that have historically had the biggest successes (i.e., revenues) due to their ability to have big impact on clinical outcomes.
Therefore, a clinical field beginning to draw much "attention" is in applications of cell therapy and tissue engineering for a [...]
The use of autologous, allogeneic and xenogeneic cells and tissues, the use of biomaterials, cell scaffolding and other approaches to tissue repair and regeneration has become part of arsenal of a number of clinical specialties, with high caseload and market revenue in these areas. In particular, orthopedics and skin applications are well established. And, while [...]
At a meeting of the FDA and the medical device industry, the FDA noted that its limited powers, such as in regulating products already on the market, in controlling how manufacturers label their products and even tracking devices when their manufacturers sell their business, may lead the agency to seek broader powers from Congress (see WSJ). Industry [...]
New medical technologies represented in specific companies recently added (January 2010) to the Medtech Startups Database:
Incubator company from shifamed.com
Developing minimally invasive therapies for end stage renal disease.
Electrical stimulation technology to restore temporary continence control for patients with colostomies.
Sonolysis for treatment of vascular thromobus disorders.
Undisclosed nanotech medical product development.
Medical robotics
Undisclosed medical technology
Tissue welding via cold plasma [...]
The number of companies with approved products and measurable revenues in the field of cell therapy and tissue engineering has exceeded the expectation of many (though not all) in the industry.
Markets such as cell/tissue are often characterized by overestimated evaluations of commercial potential and underestimated consideration of the actual challenges. Indeed many technology challenges remain [...]
With the FDA's approval of Medtronic's Melody Transcatheter Pulmonary Valve and Ensemble Delivery System (see link), another step has been made toward eliminating traditional surgery — at least that's the idea. The ability to implant a valve via a percutaneous procedure advances the art of less invasive intervention in ways akin to laparoscopic surgery, albeit at [...]
MedMarket Diligence tracks the formation of new medical technology companies through the Medtech Startup Database. The database contains records on 900 companies founded since 2001. Below is a tag cloud of keywords in company, product and technology descriptions.
The predominant clinical and technology categories covered, due to a combination of factors including principally their rate of [...]
Contact:
